NewKerala.com

India Aims for Pharma Dominance with Biopharma Shakti and Innovation Push

Health Minister JP Nadda stated India is positioned to lead the global pharmaceutical sector by focusing on innovation in biologics and biosimilars. The government has launched the Biopharma Shakti Initiative with a Rs 10,000 crore outlay to boost research and capabilities. Union Minister Anupriya Patel highlighted the need to capitalize on the expanding global biosimilars market, projected to hit $75 billion by 2030. The announcements were made at the 'India Pharma 2026' conference, which aims to foster partnerships for sectoral growth.

Key Points: India's Plan to Lead Global Pharma with Biopharma Shakti

  • Rs 10,000 crore Biopharma Shakti Initiative launched
  • Transition from generics leader to biopharma innovation hub
  • Biosimilars market projected to reach $75 billion by 2030
  • Focus on strengthening industry-academia collaboration
2 min read

India to lead global pharma landscape with innovation-driven approach: Minister

Health Minister JP Nadda announces India's shift from generics to biopharma innovation, backed by a Rs 10,000 crore initiative and key schemes.

"India is poised to lead the global pharmaceutical landscape due to its focus on biologics, biosimilars and specialty medicines - JP Nadda"

New Delhi, April 13

India is poised to lead the global pharmaceutical landscape due to its focus on biologics, biosimilars and specialty medicines, Health Minister JP Nadda said on Monday.

The minister highlighted that the government recently launched Biopharma Shakti Initiative with an outlay of Rs 10,000 crore, to advance capabilities in biopharmaceutical innovation, foster innovation and strengthen research capabilities.

Union Minister of State for Health and Family Welfare, Anupriya Patel, underlined the need for industry to intensify its focus on innovation-driven segments as innovative drugs account for nearly 87 per cent of the global pharmaceutical market value, the statement said.

Nadda mentioned complementary initiatives such as PRIP scheme for promoting research in pharmaceuticals and medical technology, Production-Linked Incentive programmes, and Pradhan Mantri Bharatiya Jan Aushadhi Pariyojana, supporting domestic manufacturing, affordable access to medicines, and deepening industry-academia collaboration as well as development of innovative therapies.

He added that the 'India Pharma 2026' event provides a vital platform to foster dialogue, partnerships, and a forward-looking roadmap for the sector.

India is undergoing a significant transition from being a global generics leader to an emerging biopharma innovation hub, Patel said.

The country currently contributes nearly 20 per cent of global generic medicines and meets around 70 per cent of global vaccine demand, underscoring the country's robust manufacturing capabilities, she added.

Emphasising future opportunities, Patel said that the global demand for biologics and biosimilars is expanding rapidly, with the biosimilars market projected to reach $75 billion by 2030.

She stressed focusing on human capital through premier institutions such as NIPERs and IITs to support advanced research and innovation.

The ministers attended 9th edition of 'India Pharma 2026', a two-day conference organised by the Department of Pharmaceuticals (DoP), in collaboration with FICCI and the Indian Pharmaceutical Alliance (IPA). The event brings together key stakeholders from across the global pharmaceutical and healthcare ecosystem, with a strong focus on innovation, self-reliance, and global leadership.

- IANS

Share this article:

Reader Comments

P
Priya S
Great vision, but execution is key. We need to ensure this funding actually reaches researchers and startups, not just big corporates. Strengthening industry-academia collaboration through IITs and NIPERs is the right step. Let's build a sustainable ecosystem.
R
Rohit P
Meeting 70% of global vaccine demand is no small feat. Our manufacturing strength is proven. Now shifting to biologics and biosimilars is the natural next step. The $75 billion market projection is huge. Jai Hind!
S
Sarah B
As someone working in the global pharma sector, India's potential is undeniable. The focus on human capital is crucial. However, to truly lead, there must be a stronger emphasis on protecting intellectual property to attract more R&D investment from multinationals.
V
Vikram M
Hope the Jan Aushadhi scheme continues to get support alongside these innovation drives. Affordable medicines for the common man cannot be forgotten in the race for high-value drugs. Balance is important.
K
Karthik V
The transition from generics leader to innovation hub is exactly what we need for long-term economic growth. PLI schemes have shown results in other sectors. Fingers crossed for pharma! Let's create more high-skilled jobs for our youth.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50